Use of Serial FDG PET to Measure the Response of Bone-Dominant Breast Cancer to Therapy
- 1 August 2002
- journal article
- research article
- Published by Elsevier in Academic Radiology
- Vol. 9 (8), 913-921
- https://doi.org/10.1016/s1076-6332(03)80461-0
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast CancerJournal of Clinical Oncology, 2001
- 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*Journal of Clinical Oncology, 2001
- Positron-emission tomographic imaging of cancer: Glucose metabolism and beyond*Seminars in Radiation Oncology, 2001
- Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary ChemotherapyJournal of Clinical Oncology, 2000
- Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast CancerJournal of Clinical Oncology, 2000
- Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.Journal of Clinical Oncology, 1998
- Mechanisms of bone metastasisCancer, 1997
- The epithelial mucin, MUC1, of milk, mammary gland and other tissuesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- The Application of Positron Emission Tomographie Imaging With Fluorodeoxyglucose to the Evaluation of Breast DiseaseAnnals of Surgery, 1992
- Bone metastases: pathophysiology and management policy.Journal of Clinical Oncology, 1991